Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement

被引：0

作者：

Pemmaraju, Naveen ^{[1
]}

Konopleva, Marina ^{[1
]}

Sweet, Kendra ^{[2
]}

Stein, Anthony ^{[3
]}

Vasu, Sumithira ^{[4
]}

Rizzieri, David ^{[5
]}

Wang, Eunice S. ^{[6
]}

Kantarjian, Hagop ^{[1
]}

Brooks, Chris ^{[7
]}

Mughal, Tariq ^{[7
]}

Lane, Andrew ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Ohio State Univ, Columbus, OH USA

[5] Duke Univ, Med Ctr, Durham, NC USA

[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[7] Stemline Therapeut Inc, New York, NY USA

[8] Dana Farber Canc Inst, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

AML; myeloid neoplasm; targeted therapy; CD123; tagraxofusp; BPDCN; Phase I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-465

引用

页码：S254 / S254

页数：1

共 42 条